Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Glutamine-mediated epigenetic regulation of cFLIP underlies resistance to TRAIL in pancreatic cancer

30 Apr 2024

Abstract excerpt

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is a promising anticancer agent because it kills cancer cells while sparing normal cells. However, many cancers, including pancreatic ductal adenocarcinoma (PDAC), exhibit intrinsic or acquired resistance to TRAIL, and the molecular mechanisms underlying TRAIL resistance in cancers, particularly in PDAC, remain unclear. In this study, we demonstrated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Cancer, Hypoxia, and Metabolism
Share to Cancer Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38684915
DOI: 10.1038/s12276-024-01231-0

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Glutamine-mediated epigenetic regulation of cFLIP underlies resistance to TRAIL in pancreatic cancerPMID 38684915Read ↗

Undermining Glutaminolysis Bolsters Chemotherapy While NRF2 Promotes Chemoresistance in KRAS-Driven Pancreatic Cancers.Semantic proximity Read ↗

TFEB Supports Pancreatic Cancer Growth through the Transcriptional Regulation of GlutaminaseSemantic proximity Read ↗

A cancer cell-intrinsic GOT2-PPARδ axis suppresses antitumor immunitySemantic proximity Read ↗

MYC/Glutamine Dependency Is a Therapeutic Vulnerability in Pancreatic Cancer with Deoxycytidine Kinase Inactivation-Induced Gemcitabine ResistanceSemantic proximity Read ↗

Glutamine-restricted diets restore sensitivity to KRASG12D inhibitor through the reversal of ANXA1 mediated metabolic reprogramming.Semantic proximity Read ↗

Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocationSemantic proximity Read ↗

Targeting pancreatic cancer glutamine dependency confers vulnerability to GPX4-dependent ferroptosisSemantic proximity Read ↗

Loss of Heterozygosity for KrasG12D Promotes Malignant Phenotype of Pancreatic Ductal Adenocarcinoma by Activating HIF-2α-c-Myc-Regulated Glutamine Metabolism.Semantic proximity Read ↗

Upregulation of the Glutaminase II Pathway Contributes to Glutamate Production upon Glutaminase 1 Inhibition in Pancreatic CancerSemantic proximity Read ↗

Oncogenic PIK3CA mutations reprogram glutamine metabolism in colorectal cancer.Semantic proximity Read ↗

A pan-cancer analysis of the glutaminase and their association with prognosis, tumor microenvironment, and therapeutic targetsSemantic proximity Read ↗

Glutamine/Serine/Glycine concentration related KDM4A expression regulated cisplatin sensitivity in gastric cancer cellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.